Why We Invest in the Future of Care

Healthcare is undergoing a seismic transformation. Rising costs, aging populations, workforce shortages, and widening disparities demand scalable, patient-centric innovations. At the same time, technology is unlocking unprecedented opportunities to improve access, outcomes, and affordability. At High Street Equity Partners (HSEP), we believe the Future of Care represents one of the most compelling investment opportunities of the next decade. We invest in technologies and business models that fundamentally improve how care is delivered, accessed, and experienced—from digital health platforms to AI-driven diagnostics, value-based care solutions, and longevity innovations.

Healthcare is not only one of the largest markets in the global economy but also one of the most innovation-hungry. In the U.S. alone, spending is projected to reach $6.2 trillion by 2028. Globally, the digital health market is expected to surpass $900 billion by 2032, fueled by the adoption of telehealth, remote monitoring, and AI in diagnostics. For investors, the opportunity is clear: early entrants who can back capital-efficient solutions stand to capture enormous long-term value while addressing humanity’s most urgent needs.

Four Core Investment Themes

Access & Affordability
Millions of patients remain locked out of high-quality healthcare due to cost, geography, or systemic inequities. We invest in platforms that expand access, reduce cost barriers, and deliver inclusive solutions across rural, suburban, and urban communities. Innovations that align digital infrastructure, policy, and design can not only reach more patients but also close longstanding gaps in equity.

Value-Based Care
The future of healthcare is moving away from fee-for-service toward outcomes-driven models. Value-based care rewards providers for delivering better care at lower cost. HSEP invests in platforms that enable providers to track performance, reduce waste, and improve outcomes—tools that align incentives across patients, providers, and payers. We see this as a massive opening for agile startups that can enable a transition long overdue in the U.S. health system.

Specialty Care
Specialty care accounts for the majority of healthcare spending, yet it suffers from long wait times, inconsistent quality, and fragmented delivery. Innovations that make specialty care more efficient and patient-centered—through telehealth, AI-assisted diagnostics, or coordinated treatment pathways—represent a large and underexplored growth market.

Longevity & Women’s Health
Two of the fastest-growing demographics—aging populations and women’s health—are underserved by existing systems. We invest in innovations that extend not just lifespan but healthspan, enabling independent living, predictive health management, and improved quality of life. In women’s health, we see a massive opportunity to close gaps in reproductive care, maternal health, and chronic conditions disproportionately affecting women.

Our Right to Win: Advisors & Ecosystem

Our conviction is strengthened by a world-class Health Tech Advisory Board, which brings together leaders across payer, provider, policy, and innovation.

• Adrian Jordan brings payer-side expertise as Plan President of Amerigroup DC, managing care for over 500,000 Medicaid members and driving innovation in value-based healthcare.
• Dr. Fernando Porter blends physician leadership with HealthTech entrepreneurship, having scaled telehealth at Doctor on Demand and integrated digital health into Privia Health.
• Dr. Sachin Nagrani pioneered home-based care as Medical Director at Heal, later acquired by Humana, and now leads Wovenly in scaling tech-enabled care delivery.
• Joel Kanter brings decades of healthcare investing experience, having supported over 450 startups with notable exits exceeding billions in value.
• Dr. Kevin Sexton is both surgeon and innovator, developing AI-driven predictive analytics and commercializing hospital technology adopted by major health systems.
• Georgie Kovacs is reshaping women’s health through Fempower Health, leveraging 20 years in biopharma and consulting to bridge patient needs with industry innovation.
• Bruce Sheppard drives value-based care transformation and market expansion through his leadership at FocusPoint Strategy Partners.
• Dr. Réda Fayek brings commercialization expertise, having guided 15+ regulated health products to market and mentored dozens of HealthTech startups.
• Dr. Darlene Walley contributes deep biotech and consumer health leadership, with $100M raised and exits exceeding $1B across health ventures.

Together, they give our portfolio companies an unrivaled advantage in navigating payer dynamics, provider adoption, regulatory hurdles, and commercialization pathways.

Management Team Alignment

Our investment team at HSEP is uniquely aligned with this thesis. Mitch Brooks (Managing Partner) has decades of experience scaling SaaS and operational playbooks. Tristan Wilkerson (Founding General Partner) brings policy expertise and a proven ability to mobilize civic and philanthropic capital. George Darden (Venture Partner) delivers operational and product leadership across healthcare and fintech. Dr. William Bowser (Principal) adds deep quantitative and economic rigor, vital for healthtech diligence. Supported by Rayshun Williams (investment analysis) and Jessica Grant (operations), our team not only invests but actively helps founders scale through sales, policy, and operational support.

The Future of Care is not a distant aspiration—it is being built today by visionary founders reimagining healthcare systems, patient experiences, and clinical outcomes. At HSEP, we are committed to backing these founders early, equipping them with capital, expertise, and networks to accelerate their impact.

For institutional investors, this means access to a disciplined, thesis-driven portfolio in one of the largest and fastest-growing sectors of the global economy. For founders, it means a partner who not only invests but actively supports you in scaling solutions that improve lives.

Healthcare is at an inflection point. The next generation of category-defining companies will not just treat patients—they will transform how care is delivered. At High Street Equity Partners, we are here to build that future, together.

‍